| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
TScan Therapeutics, Inc.
13G
TCRX · 89854M101
|
5.4% |
9/25/2026
Event 9/21/2026
|
|||
| Readout Capital, LP | 5.4% | ||||
| Readout Capital GP, LLC | 5.4% | ||||
| Matthew Smith | 5.4% | ||||
|
Precision BioSciences, Inc.
13G/A
Amendment 1
DTIL · 74019P207
|
9.4% |
8/14/2025
Event 6/30/2025
|
|||
| Readout Capital, LP | 9.3% | ||||
| Readout Capital GP, LLC | 9.3% | ||||
| ROC Holdings SPV II, LP | 7.6% | ||||
| Readout Holdings GP, LLC | 7.6% | ||||
| Matthew Smith | 9.4% | ||||
|
Precision BioSciences, Inc.
13G
DTIL · 74019P207
|
8.9% |
3/26/2025
Event 3/19/2025
|
|||
| Readout Capital, LP | 8.8% | ||||
| Readout Capital GP, LLC | 8.8% | ||||
| ROC Holdings SPV II, LP | 6.9% | ||||
| Readout Holdings GP, LLC | 6.9% | ||||
| Matthew Smith | 8.9% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.